Inactive Instrument

News IR-Med Inc. Other OTC

Equities

IRME

US46265R1032

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

IR-Med Inc.'S PressureSafe Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries	04-05	CI
IR-MED’s PressureSafe™ Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries	04-05	AQ
IR-Med Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
IR-Med Inc. and I.R Med Ltd. Appoints Aharon Klein as Interim Chief Executive Officer	03-05	CI
IR-Med Inc. Announces Cessation of Tzur Di-Cori Pursuant as Chief Executive Officer	02-28	CI
IR-Med Inc. Announces Resignation of Inna Martin as Director	02-23	CI
IR-MED Reports 92% Efficacy for PressureSafe™ in Early, Non-Invasive, Skin Color Agnostic Detection of Pressure Injuries	02-20	AQ
IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16	02-13	AQ
IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe? Device at NPIAP 2024 Annual Conference on February 16	02-13	CI
IR-MED Awarded Most Innovative Non-Invasive Diagnostics Technology Developer 2023 by Corporate Vision Magazine	12-21	AQ
IR-MED Granted Patent in Israel for its AI-Driven Platform Technology: Non-Invasive Analysis of Subcutaneous Tissue	12-07	AQ
IR-Med Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
IR-MED Appoints Healthcare Executive and Entrepreneur Tzur Di-Cori as Chief Executive Officer	04/10/23	AQ
IR-MED Announces Executive Changes Effective as of October 15, 2023	04/10/23	CI
IR-MED to Conduct Usability Study with Methodist Healthcare of San Antonio for its PressureSafe Device Which is Slated for U.S. Launch in H1 2024	26/09/23	AQ
Ir-Med to Conduct Usability Study with Methodist Healthcare of San Antonio for Its Pressuresafe Device Which Is Slated for U.S. Launch in H1 2024	26/09/23	CI
IR-MED Appoints Richard Serbin, Esq. to its Advisory Board	13/09/23	AQ
IR-Med Inc. Appoints Richard Serbin, Esq. to Its Advisory Board	13/09/23	CI
IR-MED Chairman & Interim CEO Issues Letter to Shareholders	21/08/23	AQ
IR-Med Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News IR-Med Inc. Other OTC

Equities

IRME

US46265R1032

Summary

Filters